Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832179 · ClinicalTrials.gov registry record · Phase 4
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
A Phase 4 study, sponsored by Bay Area Retina Associates.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT03832179 is a Phase 4 study that has completed, run by Bay Area Retina Associates. The registered enrollment target is 16 participants.
The verdict
NCT03832179, a Phase 4 study, has completed, sponsored by Bay Area Retina Associates.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.
Interventions
- DRUG Bevacizumab
- DRUG Aflibercept
- DRUG Ranibizumab
- DRUG Ozurdex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2024-03-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03832179
The ClinicalTrials.gov registry entry for NCT03832179 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bay Area Retina Associates, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03832179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03832179 about?
NCT03832179 is a clinical study titled "Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification". The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.
What is the current status of trial NCT03832179?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2018-11-15. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT03832179?
The interventions under investigation include: Bevacizumab (DRUG), Aflibercept (DRUG), Ranibizumab (DRUG), Ozurdex (DRUG).
Who is sponsoring clinical trial NCT03832179?
This trial is sponsored by Bay Area Retina Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.